Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, if his Department will meet with NICE, NHS England and Vertex to discuss the provision on the NHS of the drug Orkambi to treat cystic fibrosis.

The National Institute for Health and Care Excellence (NICE) is currently consulting on its draft technology appraisal guidance on the use of Orkambi (lumacaftor in combination with ivacaftor) for the treatment of cystic fibrosis in people who are homozygous for the F508del mutation. Stakeholders, including the Department, NHS England and the manufacturer, Vertex Pharmaceuticals, now have an opportunity to comment on this draft guidance.

Departmental officials remain ready to discuss any proposals from the company that could enable National Health Service patients to access the drug at a cost-effective price.

NICE expects to publish its final guidance in July 2016.